Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japanese Drug Makers See M&As For Technology, Not Size

This article was originally published in PharmAsia News

Executive Summary

An about-to-be completed merger of two Japanese drug makers represents a change in the mergers and acquisitions practice. It used to be Japanese pharmaceuticals would acquire foreign firms to become larger, but now they are likely to merge to get new technologies to make them more competitive. Kyowa Hakko Kogyo, a subsidiary of Kinn Holdings, is set to acquire Kirin Pharma on Oct. 1, to become Kyowa Hakko Kinn to take advantage of the ability to combine technology, primary in developing new antibodies. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts